secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059106
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Q1 net loss narrows to $26.8M on IGALMI revenue growth of 182% YoY
--------------------------------------------------------------------------

- IGALMI net revenue $582K (Q1 2024), up 182% YoY and 55% sequentially.
- Net loss of $26.8M vs $52.8M in Q1 2023; operating cash used $17.7M.
- Cash $74.1M at March 31, 2024, including $25M from March direct offering.
- Advanced two Phase 3 trials for BXCL501: TRANQUILITY In-Care (60 mcg) for Alzheimer's agitation and SERENITY At-Home (120 mcg) for bipolar/schizophrenia; FDA protocol submitted.
- Two new patents granted for BXCL501 (Japan and U.S.) extending protection to 2039/2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924059106/0001104659-24-059106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924059106/tm249625d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer